| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | 0.046 | 0.1 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | -0.062 | 0.1 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | 0.046 | 0.1 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.069 | 0.1 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.051 | 0.1 |
| mRNA | CGP-082996 | GDSC1000 | pan-cancer | AAC | -0.075 | 0.1 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.066 | 0.1 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | 0.069 | 0.1 |